About Civitas Therapeutics
Civitas Therapeutics is a company based in Chelsea (United States) founded in 2009 was acquired by Acorda in September 2014. Civitas Therapeutics has raised $127.81 million across 5 funding rounds from investors including Acorda, Alkermes and Orbimed. Civitas Therapeutics operates in a competitive market with competitors including Harmony Biosciences, Avidity Biosciences, Univercells, Sutro Biopharma and Vividion Therapeutics, among others.
- Headquarter Chelsea, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Civitas Therapeutics Inc
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Civitas Therapeutics
Civitas Therapeutics has successfully raised a total of $127.81M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $55.25 million completed in August 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Civitas Therapeutics
Civitas Therapeutics has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Acorda, Alkermes and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
Early-stage and late-stage biotech and finance companies are funded.
|
Locked | Locked | Locked | |
|
Private equity firm focused on life science sector
|
Locked | Locked | Locked |
Investor details for Civitas Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Civitas Therapeutics
Investment portfolio details for Civitas Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Civitas Therapeutics
Detailed financials for Civitas Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Civitas Therapeutics Comparisons
Peer comparison for Civitas Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Civitas Therapeutics
Civitas Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Harmony Biosciences, Avidity Biosciences, Univercells, Sutro Biopharma and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of therapeutics for rare neurological diseases
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
RNA-editing technologies are provided for precision medicine applications.
|
Detailed competitors of Civitas Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Civitas Therapeutics
Complete news archive for Civitas Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Civitas Therapeutics
Civitas Therapeutics was founded in 2009 and raised its 1st funding round 2 years after it was founded.
Civitas Therapeutics is headquartered in Chelsea, United States. It is registered at Chelsea, Massachusetts, United States.
Civitas Therapeutics is a funded company, having raised a total of $127.81M across 5 funding rounds to date.
Founded in 2009 and based in Chelsea, United States, Civitas Therapeutics operates as a biopharmaceutical company. A pipeline of inhaled therapeutics is developed using the ARCUS dry powder pulmonary delivery platform. The lead program, CVT-301, targets adjunctive therapy for Parkinsons disease patients experiencing OFF episodes. This involves a dry powder L-dopa formulation delivered via a reusable inhaler alongside oral regimens.
Civitas Therapeutics's top competitors include Sutro Biopharma, Avidity Biosciences and Antheia.
Civitas Therapeutics has 14 investors. Key investors include Acorda, Alkermes, Orbimed, RA Capital, and Canaan.